Company research
Regulus Therapeutics Inc.
CIK 1505512Updated Sep 26, 2026
Securities
Historical securities (1)
RGLS · OTC · equity · closed Jun 24, 2025RGLS price & chart
Historical security
This listing closed Jun 24, 2025. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 84,181,000Source | 30,750,000Source | 46,716,000Source | 68,454,000Source |
| Property, Plant and Equipment, NetUSD | 937,000Source | 1,061,000Source | 536,000Source | 281,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 25,000Source | 33,000Source | 62,000Source | 83,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 38,528,000Source | 23,767,000Source | 24,228,000Source | 60,383,000Source |
| Assets, CurrentUSD | 82,345,000Source | 28,179,000Source | 44,079,000Source | 65,235,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,015,000Source | 1,340,000Source | 1,847,000Source | 1,780,000Source |
| Operating Lease, Right-of-Use AssetUSD | 874,000Source | 1,477,000Source | 2,039,000Source | 2,564,000Source |
| Other Assets, NoncurrentUSD | — | — | 0Source | 291,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,773,000Source | 9,563,000Source | 13,425,000Source | 13,496,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 66,000Source | 20,000Source | 17,000Source | 146,000Source |
| Retained Earnings (Accumulated Deficit)USD | -559,571,000Source | -513,213,000Source | -483,176,000Source | -454,853,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 50,000Source | 0Source | -12,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 76,408,000Source | 21,187,000Source | 33,291,000Source | 54,958,000Source |
| Additional Paid in Capital, Common StockUSD | 635,858,000Source | 534,375,000Source | 516,457,000Source | 509,660,000Source |
| Liabilities and EquityUSD | 84,181,000Source | 30,750,000Source | 46,716,000Source | 68,454,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 7,499,000Source | 8,508,000Source | 11,657,000Source | 5,227,000Source |
| Operating Lease, Liability, CurrentUSD | 781,000Source | 713,000Source | 649,000Source | 589,000Source |
| Accounts Payable, CurrentUSD | 947,000Source | 204,000Source | 175,000Source | 285,000Source |
| Operating Lease, Liability, NoncurrentUSD | 274,000Source | 1,055,000Source | 1,768,000Source | 2,417,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 1,179,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 746,000Source | 691,000Source | 961,000Source | 821,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 75,800,000Source | 23,800,000Source | 39,200,000Source | — |
| Deferred Tax Liabilities, NetUSD | 361,000Source | 444,000Source | 611,000Source | 782,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 0Source | 4,673,000Source |
| Short-term InvestmentsUSD | 37,249,000Source | 0Source | 14,932,000Source | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 347,000Source | 227,000Source | 122,000Source | 459,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,735,000Source | 2,801,000Source | 2,177,000Source | 2,923,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 743,000Source | 29,000Source | -110,000Source | -250,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -41,673,000Source | -26,768,000Source | -25,526,000Source | -24,128,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -35,983,000Source | 14,491,000Source | -15,120,000Source | -251,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 340,000Source | 613,000Source | 361,000Source | 251,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 92,417,000Source | 11,816,000Source | 4,491,000Source | 53,737,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 14,761,000Source | -461,000Source | -36,155,000Source | 29,358,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 38,590,000Source | 23,829,000Source | 24,290,000Source | 60,445,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 66,000Source | 447,000Source | 491,000Source | 729,000Source |
| Income Taxes Paid, NetUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,735,000Source | 2,801,000Source | 2,177,000Source | 2,923,000Source |
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 75,800,000Source | 23,800,000Source | 39,200,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | 0Source | — | 0Source |
| General and Administrative ExpenseUSD | 14,673,000Source | 9,957,000Source | 9,829,000Source | 10,022,000Source |
| Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| InterestExpenseNonoperatingUSD | 158,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -46,358,000Source | -30,037,000Source | -28,323,000Source | -27,808,000Source |
| Operating ExpensesUSD | 50,040,000Source | 31,109,000Source | 28,239,000Source | 27,816,000Source |
| Proceeds from Issuance of Common StockUSD | -69,000Source | 1,117,000Source | 4,491,000Source | 21,431,000Source |
| Proceeds from Stock Options ExercisedUSD | 3,000Source | — | 0Source | 26,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -50,040,000Source | -31,109,000Source | -28,239,000Source | -27,816,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -46,357,000Source | -30,036,000Source | -28,322,000Source | -27,807,000Source |
| Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | -46,358,000Source | -30,037,000Source | -28,323,000Source | -27,808,000Source |
| Earnings Per Share, BasicUSD per share | -0.82Source | 1.58Source | 1.86Source | -0.32Source |
| Earnings Per Share, DilutedUSD per share | -0.82Source | 1.58Source | 1.86Source | -0.32Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 56,346,033Source | 18,960,401Source | 15,259,958Source | 85,704,535Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 56,346,033Source | 18,960,401Source | 15,259,958Source | 85,704,535Source |
| Interest Expense (non-operating)USD | 158,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Current Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| General and Administrative ExpenseUSD | 14,673,000Source | 9,957,000Source | 9,829,000Source | 10,022,000Source |
| Interest and Other IncomeUSD | 3,841,000Source | 1,677,000Source | 605,000Source | 864,000Source |
| Interest ExpenseUSD | — | 604,000Source | 688,000Source | 855,000Source |
| Operating ExpensesUSD | 50,040,000Source | 31,109,000Source | 28,239,000Source | 27,816,000Source |
| Research and Development ExpenseUSD | 35,367,000Source | 21,152,000Source | 18,410,000Source | 17,794,000Source |